{
}
UBS has maintained a Buy rating for Sarepta Therapeutics with a price target of $188, despite a recent patient death linked to its gene therapy Elevidys, which has caused the stock to drop over 26%. Analyst Eliana Merle views the market reaction as exaggerated and emphasizes the ongoing demand for Elevidys, the only approved treatment for Duchenne muscular dystrophy. While some analysts express caution regarding safety and sales forecasts, others remain optimistic about the drug's potential and future revenue growth.
Sarepta Therapeutics' shares saw volatility following a patient's death linked to its gene therapy, Elevidys, yet UBS analyst Eliana Merle maintained a Buy rating with a target of USD 188, viewing the market's reaction as an overreaction. Despite the incident, demand for Elevidys remains strong, and revenue growth is robust at 53% year-over-year. Analysts' responses vary, with some expressing caution while others uphold positive outlooks for the company's future performance.
UBS analyst Eliana Merle has reaffirmed a Buy rating on Sarepta Therapeutics (NASDAQ: SRPT) with a price target of $188.00. The positive outlook reflects confidence in the company's potential and market position.
UBS has reaffirmed its Buy rating on Madrigal Pharmaceuticals, setting a price target of $441, reflecting confidence in the company's potential in treating metabolic-associated steatohepatitis (MASH). Following strong fourth-quarter results, with revenues of $180 million and a gross margin of 96.54%, analysts remain optimistic about Madrigal's future, particularly with promising data from the Phase 3 MAESTRO-NAFLD-1 trial. The company holds a robust financial position, with cash and marketable securities totaling $931.3 million, and anticipates a potential European launch of its drug Rezdiffra in 2025, pending regulatory approval.
UBS has initiated coverage on Tyra Biosciences (NASDAQ: TYRA) with a Buy rating and a price target of $28, citing strong potential for its drug candidate TYRA-300, which targets non-muscle invasive bladder cancer and achondroplasia. The stock has gained 15.54% recently, and analysts project significant upside, with UBS estimating long-term sales of $350 million for oncology and $650 million for growth disorders by 2035. Positive data updates could lead to over 100% share price growth in the next 12 to 18 months, reflecting confidence in the company's innovative drug development and financial health.
Eliana Merle
People
The information provided herein is generated by experimental artificial intelligence and is for informational purposes only.
analysts divided on sarepta therapeutics after patient death linked to elevidys
United States Dollar
JPMorgan U.S. Research Enhanced Large Cap ETF
Leerink Partners LLC
Arrowhead Pharmaceuticals, Inc.
REGENXBIO Inc.
Cantor Fitzgerald Equity Opp A
H.C. Wainwright & Co. LLC
Sarepta Therapeutics, Inc.
USA
Eliana Merle
Show more
16:08 19.03.2025
analysts divided on sarepta therapeutics after patient death linked to elevidys
United States Dollar
JPMorgan U.S. Research Enhanced Large Cap ETF
Leerink Partners LLC
Arrowhead Pharmaceuticals, Inc.
REGENXBIO Inc.
Cantor Fitzgerald Equity Opp A
H.C. Wainwright & Co. LLC
Sarepta Therapeutics, Inc.
USA
Eliana Merle
Show more
16:08 19.03.2025
ubs maintains buy rating and price target for sarepta therapeutics
15:19 19.03.2025
ubs maintains buy rating on madrigal pharmaceuticals with target price of 441
17:17 27.02.2025
ubs initiates buy rating for tyra biosciences with strong growth potential
Tyra Biosciences, Inc.
Piper Sandler Cos
H.C. Wainwright & Co. LLC
Nasdaq 100 Mar 25
USA
Eliana Merle
Show more
13:38 07.01.2025
Trending
Subcategory
Corporate News
Stock Market Updates
Industry Trends
Industry Mergers & Acquisitions
Finance Mergers & Acquisitions
Global Financial Events
Banking Regulations
Global Trade Developments
Domestic Politics
Retail and Consumer Goods
Central Bank Actions
CEO Changes
Government Policies
Workplace Trends
Market Analysis and Predictions
Startups & Entrepreneurship
Elections & Campaigns
Government Economic Policies
Inflation and Monetary Impact
Supply Chain Management
Countries:
Companies:
Tesla, Inc.
Barclays PLC
JPMorgan Chase & Co.
Deutsche Bank Money Market PP
Apple Inc.
UniCredit S.p.A.
Banco BPM S.p.A.
Credit Suisse Strategic Income I
The Goldman Sachs Group, Inc.
UBS Group AG
SpaceXCoin USD
BNP Paribas SA
Lloyds Banking Group plc
Banco Santander, S.A.
CREDIT AGRICOLE
Amazon.com, Inc.
Credit Agricole
Berkshire Hathaway Inc.
Reinsurance Group of America, Incorporated
Google Inc.
Currencies:
United States Dollar
Euro
British Pound Sterling
Swiss Franc
Chinese Yuan
Japanese Yen
Indian Rupee
South Korean Won
Canadian Dollar
Australian Dollar
Hong Kong Dollar
Offshore Chinese Yuan
Singapore Dollar
Mexican Peso
Vietnamese Đồng
Indonesian Rupiah
Thai Baht
Norwegian Krone
Swedish Krona
Filipino Peso
People: